Cécile Chartier

3.5k total citations · 1 hit paper
24 papers, 1.7k citations indexed

About

Cécile Chartier is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Cécile Chartier has authored 24 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Oncology and 6 papers in Genetics. Recurrent topics in Cécile Chartier's work include Virus-based gene therapy research (6 papers), CAR-T cell therapy research (6 papers) and Cancer Research and Treatments (3 papers). Cécile Chartier is often cited by papers focused on Virus-based gene therapy research (6 papers), CAR-T cell therapy research (6 papers) and Cancer Research and Treatments (3 papers). Cécile Chartier collaborates with scholars based in United States, France and Germany. Cécile Chartier's co-authors include Andréa Pavirani, A Dieterlé, Majid Mehtali, Eric Degryse, Murielle Gantzer, John Lewicki, Austin Gurney, Stephanie Smith‐Berdan, Scott J. Dylla and Jorge Aguilar and has published in prestigious journals such as PLoS ONE, Cancer Research and Journal of Virology.

In The Last Decade

Cécile Chartier

22 papers receiving 1.7k citations

Hit Papers

Efficient generation of r... 1996 2026 2006 2016 1996 100 200 300 400 500

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Cécile Chartier 1.1k 895 731 232 203 24 1.7k
Kilian Guse 717 0.7× 570 0.6× 781 1.1× 127 0.5× 68 0.3× 32 1.3k
Heung Chong 874 0.8× 537 0.6× 758 1.0× 498 2.1× 51 0.3× 36 1.5k
Zeng B. Zhu 823 0.8× 552 0.6× 776 1.1× 387 1.7× 62 0.3× 45 1.4k
Phyllis B. Blair 796 0.7× 914 1.0× 686 0.9× 530 2.3× 190 0.9× 76 2.1k
Stefan Imreh 864 0.8× 855 1.0× 278 0.4× 417 1.8× 205 1.0× 43 1.8k
Marie‐Claude Bourgeois‐Daigneault 561 0.5× 1.0k 1.2× 542 0.7× 1.0k 4.4× 111 0.5× 37 1.9k
Irene Kuhn 444 0.4× 383 0.4× 364 0.5× 145 0.6× 99 0.5× 21 1.0k
A. Bout 1.2k 1.1× 610 0.7× 1.3k 1.7× 166 0.7× 39 0.2× 42 1.9k
M Pettersson 1.3k 1.2× 424 0.5× 279 0.4× 229 1.0× 166 0.8× 25 1.8k
Angela C. Bradshaw 885 0.8× 293 0.3× 600 0.8× 133 0.6× 280 1.4× 38 1.3k

Countries citing papers authored by Cécile Chartier

Since Specialization
Citations

This map shows the geographic impact of Cécile Chartier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cécile Chartier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cécile Chartier more than expected).

Fields of papers citing papers by Cécile Chartier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cécile Chartier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cécile Chartier. The network helps show where Cécile Chartier may publish in the future.

Co-authorship network of co-authors of Cécile Chartier

This figure shows the co-authorship network connecting the top 25 collaborators of Cécile Chartier. A scholar is included among the top collaborators of Cécile Chartier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cécile Chartier. Cécile Chartier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jazaeri, Amir A., Viktoria Gontcharova, Mark A. T. Blaskovich, et al.. (2020). 873P In vivo persistence of Iovance tumour-infiltrating lymphocytes LN-145 in cervical cancer patients. Annals of Oncology. 31. S642–S642. 5 indexed citations
2.
Ritthipichai, Krit, et al.. (2020). 1052P Genetic modification of Iovance’s TIL through TALEN-mediated knockout of PD-1 as a strategy to empower TIL therapy for cancer. Annals of Oncology. 31. S720–S720. 13 indexed citations
3.
Simpson-Abelson, Michelle R., et al.. (2020). 1053P Iovance generation-2 tumour-infiltrating lymphocyte (TIL) product is reinvigorated during the manufacturing process. Annals of Oncology. 31. S720–S720. 2 indexed citations
4.
Fardis, Maria, et al.. (2020). Current and future directions for tumor infiltrating lymphocyte therapy for the treatment of solid tumors. Cell and Gene Therapy Insights. 6(6). 855–863. 7 indexed citations
5.
Fischer, Marcus, Belinda Cancilla, Vincent Yeung, et al.. (2017). WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Science Advances. 3(6). e1700090–e1700090. 122 indexed citations
7.
Chartier, Cécile. (2008). Françoise Canon-Roger & Christine Chollier, Des genres aux textes : Essais de sémantique interprétative en littérature de langue anglaise. Études irlandaises. 33(2). 173–174.
8.
Dylla, Scott J., Lucia Beviglia, In‐Kyung Park, et al.. (2008). Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy. PLoS ONE. 3(6). e2428–e2428. 448 indexed citations
9.
Kuhn, Irene, Paul Harden, Maxine Bauzon, et al.. (2008). Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer. PLoS ONE. 3(6). e2409–e2409. 153 indexed citations
10.
Dylla, Scott J., Lucia Beviglia, Inkyung Park, et al.. (2008). Correction: Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy. PLoS ONE. 3(8). 39 indexed citations
11.
Elit, Laurie, Cécile Chartier, Amit M. Oza, et al.. (2006). Outcomes for systemic therapy in women with ovarian cancer. Gynecologic Oncology. 103(2). 554–558. 15 indexed citations
12.
Kretschmer, Peter J., Fang Jin, Cécile Chartier, & Terry Hermiston. (2005). Development of a transposon-based approach for identifying novel transgene insertion sites within the replicating adenovirus. Molecular Therapy. 12(1). 118–127. 11 indexed citations
13.
Kleeberg, Ulrich R., Stefan Suciu, E.‐B. Bröcker, et al.. (2003). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. European Journal of Cancer. 40(3). 390–402. 145 indexed citations
14.
Bröcker, Eva-Bettina, F. Lejeune, Cécile Chartier, et al.. (1999). Adjuvant trial in melanoma patients comparing rIFN-α to rIFN-γ to Iscador to a control group after curative resection of high risk primary (≥3 MM) or regional lymphnode metastasis (EORTC 18871). European Journal of Cancer. 35. S82–S82. 48 indexed citations
15.
Chartier, Cécile, Eric Degryse, Murielle Gantzer, et al.. (1996). Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. Journal of Virology. 70(7). 4805–4810. 591 indexed citations breakdown →
16.
Dupuit, Florence, Cécile Chartier, Nathalie Accart, et al.. (1996). Targeting cell-specific gene expression with an adenovirus vector containing the lacZ gene under the control of the CFTR promoter.. PubMed. 3(1). 49–58. 32 indexed citations
17.
Imler, Jean‐Luc, Cécile Chartier, Dominique Dreyer, et al.. (1996). Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors.. PubMed. 3(1). 75–84. 47 indexed citations
18.
Perraud, F., Kazuya Yoshimura, B. Gregory Louis, et al.. (1992). The promoter of the human cystic fibrosis transmembrane conductance regulator gene directing SV40 T antigen expression induces malignant proliferation of ependymal cells in transgenic mice.. PubMed. 7(5). 993–7. 10 indexed citations
19.
Truchetet, F., et al.. (1990). D.N.C.B. for malignant melanoma: significance in the treatment strategy.. PubMed. 9(6). 1531–6. 9 indexed citations
20.
Chartier, Cécile, et al.. (1987). [Atrial natriuretic hormone and regulation of water-electrolyte balance and the circulating blood volume].. PubMed. 35(2). 107–13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026